NASDAQ: AZNAstrazeneca Plc Stock
$60.22+0.55 (+0.92%)
Updated Oct 15, 2021
AZN Price
$60.22
Fair Value Price
N/A
Market Cap
$158.02B
52 Week Low
$46.48
52 Week High
$61.34
P/E
41.82x
P/B
10.08x
P/S
5.32x
PEG
0.97x
Dividend Yield
2.32%
Revenue
$29.53B
Earnings
$3.77B
Gross Margin
76.5%
Operating Margin
19.19%
Profit Margin
12.8%
Debt to Equity
3.7
Operating Cash Flow
$6B
Beta
0.57
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Score
High
Medium
Low
42
Industry average
Reasons for this score
AZN ($60.22) is trading below its intrinsic value of $214.49, according to Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Valuation
AZN is poor value based on its earnings relative to its share price (41.82x), compared to the US market average (4.4x)
Valuation
AZN is poor value based on its earnings relative to its share price (41.82x), compared to the US Drug Manufacturers - General industry average (22.54x)
Valuation
AZN News
Valuation
AZN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
41.82x
Industry
22.54x
Market
4.4x
AZN is poor value based on its earnings relative to its share price (41.82x), compared to the US market average (4.4x)
Valuation
AZN is poor value based on its earnings relative to its share price (41.82x), compared to the US Drug Manufacturers - General industry average (22.54x)
Valuation
AZN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.08x
Industry
5.12x
AZN is poor value based on its book value relative to its share price (10.08x), compared to the US Drug Manufacturers - General industry average (5.12x)
Valuation
AZN price to earnings growth (PEG)
For valuing profitable companies with growth potential
AZN is good value based on it's Price to Earnings and rate of earnings growth, measured by PEG ratio (0.97x)
Valuation
AZN's financial health
Profit margin
Revenue
$8.2B
Net Income
$550.0M
Profit Margin
6.7%
AZN's Earnings (EBIT) of $5.67B are insufficient to safely cover interest payments on company debt ($27.50B)
Financials
AZN's profit margin has increased (+4.8%) in the last year from (8%) to (12.8%)
Financials
Assets to liabilities
Assets
$73.6B
Liabilities
$57.9B
Debt to equity
1.75
AZN's short-term assets ($27.27B) exceed its short-term liabilities ($22.22B)
Financials
AZN's long-term liabilities ($35.73B) exceed its short-term assets ($27.27B)
Financials
AZN's debt has increased relative to shareholder equity (3.7), over the past 5 years ago (3.62)
Financials
AZN's debt to equity ratio (3.7) is considered high
Financials
Cash flow
Operating
$892.0M
Investing
-$236.0M
Financing
$7.3B
AZN's operating cash flow ($6.45B) is sufficient to service the company's debt ($27.50B)
Financials
Astrazeneca Stock FAQ
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.